目的 研究芪蛭膠囊聯(lián)合阿托伐他汀和依折麥布治療老年冠心病合并高脂血癥的臨床療效。方法 選取2014年3月—2015年3月咸陽市第一人民醫(yī)院心血管內(nèi)科收治的老年冠心病合并高脂血癥患者110例,隨機分為對照組和治療組,每組各55例。對照組在基礎治療上口服阿托伐他汀鈣片,1片/次,1次/d;同時口服依折麥布片,1片/次,1次/d。治療組在對照組的基礎上口服芪蛭膠囊,2粒/次,3次/d。兩組均連續(xù)治療8周。觀察兩組患者的臨床療效,比較兩組患者治療前后三酰甘油(TG)、總膽固醇(TC)、高密度脂蛋白膽固醇(HDL-C)、低密度脂蛋白膽固醇(LDL-C)的變化,同時比較兩組心血管不良事件的發(fā)生情況。結果 治療后,對照組和治療組冠心病總有效率分別為78.18%、89.09%;兩組血脂總有效率分別為72.73%、87.27%,兩組冠心病總有效率和血脂總有效率比較差異均有統(tǒng)計學意義(P <0.05)。治療后,兩組TC、TG、LDL-C均較治療前顯著降低,HDL-C顯著升高,同組治療前后差異有統(tǒng)計學意義(P <0.05);且治療組這些觀察指標的改善程度優(yōu)于對照組,兩組比較差異有統(tǒng)計學意義(P <0.05)。對照組和治療組心血管不良事件發(fā)生率分別為29.09%、7.27%,兩組比較差異有統(tǒng)計學意義(P <0.05)。結論 芪蛭膠囊聯(lián)合阿托伐他汀和依折麥布治療老年冠心病合并高脂血癥具有較好的臨床療效,能顯著降低患者血脂水平,降低心血管不良事件的發(fā)生率,具有一定的臨床推廣應用價值。

Objective To observe the clinical curative effect of Qizhi Capsules combined with atorvastatin and ezetimibe in treatment of elderly coronary heart disease with hyperlipidemia. Methods Patients (110 cases) with coronary heart disease with hyperlipidemia in Department of Cardiovascular Internal Medicine of the First People's Hospital of Xianyang City from March 2014 to March 2015 were randomly divided into control and treatment groups, and each group had 55 cases. The patients in control group were po administered with Atorvastatin Calcium Tablets on the basis of foundation treatment, 1 tablet/time, once daily. At the same time, they were po administered with Ezetimibe Tablets, 1 tablet/time, once daily. The patients in treatment group were po administered with Qizhi Capsules on the basis of control group, 2 grains/time, three times daily. Two groups were treated for 8 weeks. After treatment, the efficacy was evaluated. The changes of TC, TG, LDL-C, HDL-C, and the occurrence of cardiovascular adverse events in two groups were compared. Results The clinical efficacies of coronary heart disease in control and treatment groups were 78.18% and 89.09%, respectively, while clinical efficacies of blood lipid in two groups were 72.73% and 87.27%, respectively, and there were differences between two groups (P < 0.05). After treatment, TG, TC, and LDL-C in two groups were significantly reduced, while HDL-C was significantly increased, and the difference was statistically significant in the same group (P < 0.05). And these indicators in treatment group improved better than those in the control group, with significant differences between two groups (P < 0.05). The incidence of cardiovascular adverse events in the control and treatment groups were 29.09% and 7.27%, respectively, and there were differences between two groups (P < 0.05). Conclusion Qizhi Capsules combined with atorvastatin and ezetimibe has good clinicalefficacy in treatment of elderly coronary heart disease with hyperlipidemia, and can significantly decrease blood lipid level, and also can reduce the incidence of cardiovascular adverse events, which has a certain clinical application value.